Rosiglitazone (peroxisome proliferator-activated receptor-gamma) counters hypertension and adverse cardiac and vascular remodeling in 2K1C hypertensive rats

Experimental and Toxicologic Pathology

Volumn 63, Issue 1-2, 2011, Pages 1-7

  de Oliveira Silva Junior, Geraldo ^a   da Silva Torres, Thiago ^a   de Souza Mendonca, Leonardo ^a   Alberto Mandarim de Lacerda Carlos, C ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Angiotensin II type 1 receptor; PPAR gamma agonist; Remodeling; Renovascular hypertension; Stereology

Indexed keywords

HYDRALAZINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE;

2K1C HYPERTENSIVE RAT; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTERY MUSCLE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CELL NUCLEUS; CELL VOLUME; COMMON CAROTID ARTERY; CONTROLLED STUDY; HEART DISEASE; HEART LEFT VENTRICLE; HEART MUSCLE CELL; MALE; MORNING DOSAGE; NONHUMAN; RAT; RAT STRAIN; RENOVASCULAR HYPERTENSION; SHAM PROCEDURE; SMOOTH MUSCLE FIBER; THORACIC AORTA; VASCULAR DISEASE; WISTAR RAT;

ANIMALS; AORTA; CAROTID ARTERY, COMMON; HYPERTENSION, RENOVASCULAR; IMMUNOHISTOCHEMISTRY; INSULIN; LEPTIN; MALE; MYOCARDIUM; PPAR GAMMA; RATS; RATS, INBRED SHR; RATS, WISTAR; THIAZOLIDINEDIONES; TUNICA INTIMA;

RATTUS; RATTUS NORVEGICUS;

EID: 78650172971     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etp.2009.09.001     Document Type: Article

References (34)

1. Ali S.S., Igwe R.C., Walsh M.F., Sowers J.R. Troglitazone and vascular reactivity: role of glucose and calcium. Metabolism 1999, 48:125-130.
2. Benkirane K., Viel E.C., Amiri F., Schiffrin E.L. Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 2006, 47:102-108.
3. Bolten C.W., Payne M.A., McDonald W.G., Blanner P.M., Chott R.C., Ghosh S., et al. Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat. Diab Vasc Dis Res 2007, 4:117-123.
4. El Mabrouk M., Touyz R.M., Schiffrin E.L. Differential ANG II-induced growth activation pathways in mesenteric artery smooth muscle cells from SHR. Am J Physiol Heart Circ Physiol 2001, 281:H30-0.
5. Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004, 53(Suppl 1):S43-S50.
6. Fullmer H.M., Lillie R.D. A selective stain for elastic tissue (orcinol-new fuchsin). Stain Technol 1956, 31:27-29.
7. Gao D.F., Niu X.L., Hao G.H., Peng N., Wei J., Ning N., et al. Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells - role of PPAR-gamma in vascular fibrosis. Biochem Pharmacol 2007, 73:185-197.
8. Gonon A.T., Bulhak A., Labruto F., Sjoquist P.O., Pernow J. Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide. Basic Res Cardiol 2007, 102:80-89.
9. Grimaldi P.A. The roles of PPARs in adipocyte differentiation. Prog Lipid Res 2001, 40:269-281.
10. He W. PPARgamma2 polymorphism and human health. PPAR Res 2009, 2009:849538.
11. Home P.D., Pocock S.J., Beck-Nielsen H., Gomis R., Hanefeld M., Jones N.P., et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007, 357:28-38.
12. Ishibashi M., Egashira K., Hiasa K., Inoue S., Ni W., Zhao Q., et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002, 40:687-693.
13. Kagiyama S., Varela A., Phillips M.I., Galli S.M. Antisense inhibition of brain renin-angiotensin system decreased blood pressure in chronic 2-kidney, 1 clip hypertensive rats. Hypertension 2001, 37:371-375.
14. Krall R.L. Cardiovascular safety of rosiglitazone. Lancet 2007, 369:1995-1996.
15. Mamnoor P.K., Hegde P., Datla S.R., Damarla R.K., Rajagopalan R., Chakrabarti R. Antihypertensive effect of ragaglitazar: a novel PPARalpha and gamma dual activator. Pharmacol Res 2006, 54:129-135.
16. Mandarim-de-Lacerda C.A. Stereological tools in biomedical research. An Acad Bras Cienc 2003, 75:469-486.
17. Mandarim-de-Lacerda C.A., Passos M.A., Sampaio F.J. Quantitative study of the heart in 2 human twin embryos at 14mm C-R (stage 18). Acta Anat (Basel) 1987, 130:224-227.
18. Martyn C.N., Greenwald S.E. Impaired synthesis of elastin in walls of aorta and large conduit arteries during early development as an initiating event in pathogenesis of systemic hypertension. Lancet 1997, 350:953-955.
19. Mendonca L.S., Fernandes-Santos C., Mandarim-de-Lacerda C.A. Cardiac and aortic structural alterations due to surgically-induced menopause associated with renovascular hypertension in rats. Int J Exp Pathol 2007, 88:301-309.
20. Mill J.G., Milanez Mda C., de Resende M.M., Gomes Mda G., Leite C.M. Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. Clin Exp Pharmacol Physiol 2003, 30:739-744.
21. Molavi B., Chen J., Mehta J.L. Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. Am J Physiol 2006, 291:H687-H693.
22. Nagai M., Horikoshi K., Izumi T., Seki S., Taniguchi M., Taniguchi I., et al. Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats. Cardiovasc Drugs Ther 2004, 18:353-362.
23. Negro R., Mangieri T., Dazzi D., Pezzarossa A., Hassan H. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diab Res Clin Pract 2005, 70:20-25.
24. Nejjar I., Pieraggi M.T., Thiers J.C., Bouissou H. Age-related changes in the elastic tissue of the human thoracic aorta. Atherosclerosis 1990, 80:199-208.
25. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
26. Olivetti G., Anversa P., Melissari M., Loud A.V. Morphometry of medial hypertrophy in the rat thoracic aorta. Lab Invest 1980, 42:559-565.
27. Pereira L.M., Bezerra D.G., Mandarim-de-Lacerda C.A. Aortic wall remodeling in rats with nitric oxide deficiency treated by enalapril or verapamil. Pathol Res Pract 2004, 200:211-217.
28. Sarafidis P.A., Lasaridis A.N., Nilsson P.M., Pagkalos E.M., Hitoglou-Makedou A.D., Pliakos C.I., et al. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 2004, 22:1769-1777.
29. Smith S.R., De Jonge L., Volaufova J., Li Y., Xie H., Bray G.A. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 2005, 54:24-32.
30. Takeda K., Ichiki T., Tokunou T., Funakoshi Y., Iino N., Hirano K., et al. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 2000, 102:1834-1839.
31. Torres T.S., Silva G.D., Aguila M.B., de Carvalho J.J., Mandarim-De-Lacerda C.A. Effects of rosiglitazone (a peroxysome proliferator-activated receptor gamma agonist) on the blood pressure and aortic structure in metabolically programmed (perinatal low protein) rats. Hypertens Res 2008, 31:965-975.
32. Villacorta L., Schopfer F.J., Zhang J., Freeman B.A., Chen Y.E. PPARgamma and its ligands: therapeutic implications in cardiovascular disease. Clin Sci (Lond) 2009, 116:205-218.
33. Wu L., Wang R., De Champlain J., Wilson T.W. Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am J Hypertens 2004, 17:749-756.
34. Yue T.L., Bao W., Gu J.L., Cui J., Tao L., Ma X.L., et al. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005, 54:554-562.